Drugmakers delay some European launches with a wary eye on Trump’s pricing policies

Drug launches in EU markets fell ~35% in the 10 months after the U.S. introduced international reference pricing versus the prior 10 months, as companies delay European launches to avoid depressing prices in the ~$700bn U.S. market. Examples include Insmed postponing its Germany launch of Brunspri and Amgen withdrawing Repatha from Denmark; over 90% of drugs approved in 2025 first launched in the U.S., underscoring a U.S.-first strategy. Expect slower EU launch cadence, increased launch-timing uncertainty and potential downside to European access and R&D investment; monitor MFN/reference-pricing policy developments and companies with large U.S. exposure (e.g., Amgen, Insmed, Roche, Novartis, AstraZeneca).

Analysis

The policy-driven re-pricing dynamic is effectively making launch sequencing a deliberate financial lever rather than a clinical/commercial decision, which concentrates early revenues into fewer geographies and lengthens the cash-flow tail elsewhere. For an average mid-sized launch, re-sequencing that defers 20-30% of first-two-year patient uptake into later years increases NPV sensitivity to discount rates and raises the value of “first-to-US” positioning by a similar order of magnitude.

Second-order winners are firms and service providers that monetize US-first commercialization (strong US payer negotiating power, large salesforce scale, and US-focused distribution), while companies relying on European national payer negotiations or on rapid multi-market rollouts face both top-line and valuation compression. Biotech cost-of-capital will rise where EU launches were a pre-built de-risking milestone for follow-on financing; expect a visible IPO/secondary slowdown in Europe and cross-border M&A pressure favoring acquirers with hefty US balance sheets.

Key catalysts that will flip the pattern are near-term regulatory clarifications or carve-outs (weeks–months) and legal or trade challenges (months–years); a quick administrative safe-harbor for staged launches would materially truncate downside, while entrenched enforcement would prolong revenue deferrals for multiple fiscal years. Watch quarterlies for guidance changes and early-stage program re-prioritisations — these will be the earliest observable evidence the market can trade against.

Key Decisions for Investors

• Short INSM (tactical): buy 6–9 month ATM puts sized for a 30–50% downside scenario if EU commercialization remains deferred; hedge tail risk by pairing with a long-dated (18-month) call at 1/3 notional to capture a policy reversal. Expect 2–3x return on premium if launches are postponed materially.
• Pair trade — long SMCI or APP vs short AZN (sector rotation): buy 6–12 month call options on SMCI or APP (tech/infra exposure) and fund with 6–12 month puts on AZN. Rationale: rotate from European pricing-vulnerable pharmas into tech beneficiaries of US-centric commercialization; target asymmetric 1.5–2x upside vs limited premium risk.
• Short small-cap, EU-dependent producers (INDV): initiate outright short or buy 9–12 month puts sized to 20–40% downside, and set alerts to tighten on any administrative clarification. Time risk: 3–12 months — the largest moves will cluster around regulatory pronouncements or company-level launch updates.
• Event hedge for large-cap exposure (AMGN, NVS): if net long big pharmas for other reasons, buy 12–18 month protective put collars (sell OTM calls to finance) to limit a policy-driven sell-off while retaining dividend/cash-flow exposure; cost-effective way to preserve upside if policy softens within 6–12 months.